MedTrace Logo

Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

NCT07672431 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-06-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work better than the standard of care alone. The main questions it aims to answer is:

* will the addition of the TheraBionic P1 device to standard of care third line treatment affect progression free and overall survival in these participants

Conditions

Interventions

DEVICE

TheraBionic P1

TheraBionic P1 is amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) device added to any third line treatment for triple negative breast cancer

Sponsors & Collaborators

  • THERABIONIC INC.

    collaborator OTHER

  • Ucancervive

    collaborator UNKNOWN

  • Barbara Ann Karmanos Cancer Institute

    lead OTHER

Principal Investigators

  • Jailan Elayoubi, M.D. · Barbara Ann Karmanos Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07672431 on ClinicalTrials.gov